Results 21 to 30 of about 4,315,874 (223)

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

Hepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei   +9 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Disseminated tuberculosis with myelofibrosis presentation: a case report

Journal of Medical Case Reports, 2021
Background Primary myelofibrosis is a rare myeloproliferative disorder in middle-aged and old adults and should be distinguished from secondary and reactive causes of bone marrow fibrosis because, in reactive fibrosis, treatment approaches depend on the ...
Mahdi Khatuni, Marziyeh Ghalamkari, Fereshteh Ameli, Habibeh Yekehtaz   +3 more
doaj   +1 more source

Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity

Frontiers in Pediatrics, 2022
Myelofibrosis is a rare myeloproliferative disorder. The detailed descriptions of myelofibrosis in children and adolescents is limited to a few case series and case reports describing fewer than 100 patients, thus suggesting the extreme rarity of this ...
Fabiola Guerra, Fabiola Guerra, Vincenzo L’Imperio, Sonia Bonanomi, Marco Spinelli, Tiziana Angela Coliva, Fabiola Dell’Acqua, Giulia Maria Ferrari, Paola Corti, Adriana Balduzzi, Andrea Biondi, Fabio Pagni, Francesco Saettini   +12 more
doaj   +1 more source

Correlation between Primary Myelofibrosis and the Association of Portal Thrombosis with Portal-Biliary Cavernoma: US, MDCT, and MRI Features

Journal of Gastrointestinal and Abdominal Radiology, 2021
Objective Myelofibrosis is a rare chronic myelolymphoproliferative disease and is associated with increased risk of venous thromboembolism. The objective of this study is to retrospectively evaluate patients with primary myelofibrosis who underwent ...
Marco Di Girolamo, Stefania Galassi, Salvatore Merola, Paolo Bonome, Esmeralda Conte, Elsa Iannicelli   +5 more
doaj   +1 more source

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

Haematologica, 2010
Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer, Peter J. Campbell, Anthony R. Green   +2 more
doaj   +1 more source

Correlation of cytogenetics and grade of bone marrow fibrosis in primary myelofibrosis [PDF]

Srpski Medicinski Časopis Lekarske Komore
Introduction/Aim: Primary myelofibrosis is a clonal myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis.
Đorđević Vesna, Peruničić-Jovanović Maja, Šefer Dijana, Bižić-Radulović Sandra, Soldatović Ivan, Todorović-Balint Milena   +5 more
doaj   +1 more source

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis

Haematologica, 2012
Background The World Health Organization classification of myeloproliferative neoplasms discriminates between essential thrombocythemia and the prefibrotic phase of primary myelofibrosis.
Thomas Buhr, Konnie Hebeda, Vassiliki Kaloutsi, Anna Porwit, Jon Van der Walt, Hans Kreipe   +5 more
doaj   +1 more source

The human myeloproliferative disorders: molecular pathogenesis and clonal heterogeneity [PDF]

, 2010
The classical myeloproliferative disorders (MPD), comprising essential thrombocythaemia (ET), polycythaemia vera (PV) and idiopathic myelofibrosis (IMF), are clonal premalignant haematopoietic neoplasms associated with activating mutations in signalling ...

core   +2 more sources

Primary Myelofibrosis with Mesenteric Extramedullary Haematopoiesis [PDF]

Journal of Clinical and Diagnostic Research, 2018
Primary myelofibrosis or chronic idiopathic myelofibrosis is a myeloproliferative neoplasm characterized by proliferation of abnormal haematopoietic stem cells in bone marrow resulting in replacement of marrow with fibrotic scar tissue.
Saurabh Kumar, Shaloo Shaloo, Juhi Chawla, Subha Ashok, Shalini Thapar Laroia   +4 more
doaj   +1 more source